CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $14.54M, lower than 95% of all stocks globally
- PositionProfit margin is 454.9%, higher than 95% of its Biotechnology peers (median -45.7%)
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
400.11MUSDvs all stocks (USD)
Trailing P/E
7.67xvs Biotechnology peers
Revenue (TTM)
14.54MUSDvs all stocks (USD)
Profit Margin
454.86%vs Biotechnology peers
Beta
1.33xvs all stocks
52-Week Change
7.81%vs all stocks
Market Capitalization
400.11MUSDvs all stocks (USD)
Enterprise Value
257.29MUSDvs all stocks (USD)
Trailing P/E
7.67xvs Biotechnology peers
Forward P/E
25.43xvs Biotechnology peers
PEG Ratio
0.3069xvs Biotechnology peers
Price to Sales (TTM)
28.58xvs Biotechnology peers
Price to Book (MRQ)
2.86xvs Biotechnology peers
Enterprise to Revenue
17.70xvs Biotechnology peers
Enterprise to EBITDA
-2.86xvs Biotechnology peers
Gross Margin
69.08%vs Biotechnology peers
Profit Margin
454.86%vs Biotechnology peers
Operating Margin
-264.14%vs Biotechnology peers
Return on Assets (TTM)
-38.92%vs Biotechnology peers
Return on Equity (TTM)
70.99%vs Biotechnology peers
Revenue (TTM)
14.54MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2660USDUpdated Jul 17, 2026Quarterly Revenue Growth
60.89%vs Biotechnology peers
Gross Profit (TTM)
-18.01MUSDvs all stocks (USD)
EBITDA (TTM)
72.45MUSDvs all stocks (USD)
Net Income (TTM)
66.14MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-77.73MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-56.59MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
5.82MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
3.42MUSDFY2025 · Dec 31, 2025Gross Profit
2.40MUSDFY2025 · Dec 31, 2025Operating Income
-89.45MUSDvs all stocks (USD)
Pre-tax Income
71.28MUSDFY2025 · Dec 31, 2025Income Tax Expense
100.00KUSDFY2025 · Dec 31, 2025Net Income
71.18MUSDFY2025 · Dec 31, 2025EBIT
75.02MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
72.45MUSDFY2025 · Dec 31, 2025Research & Development
26.81MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
65.03MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
5.56MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
3.74MUSDFY2025 · Dec 31, 2025EPS (Basic)
1.34USDFY2025 · Dec 31, 2025EPS (Diluted)
1.01USDFY2025 · Dec 31, 2025Basic Shares Outstanding
52.95MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
52.95MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
71.18MUSDFY2025 · Dec 31, 2025Operating Cash Flow
82.20MUSDFY2025 · Dec 31, 2025Free Cash Flow
82.20MUSDDerived from operating cash flow minus capital expenditure. This filing charges 3.56M of depreciation against 0 of capital expenditure, and its own free-cash-flow line reads -84.3M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
78.44MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Interest Paid
2.59MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
71.18MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.56MUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.78MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.04MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-5.06MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.54MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-6.84MUSDFY2025 · Dec 31, 2025Capital Expenditures
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-206.63MUSDFY2025 · Dec 31, 2025Sale of Investments
167.27MUSDFY2025 · Dec 31, 2025Other Investing Activity
152.37MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
113.00MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-37.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
17.26MUSDFY2025 · Dec 31, 2025Shares Outstanding
56.87MSharesUpdated Jul 17, 2026Float Shares
36.62MSharesUpdated Jul 17, 2026Shares Short
13.68MSharesUpdated Jul 17, 2026Short Ratio
11.22daysvs all stocks
Short % of Shares Outstanding
25.77%vs all stocks
% Held by Insiders
16.59%vs all stocks
% Held by Institutions
70.37%vs all stocks
Total Cash (MRQ)
168.27MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.95USDUpdated Jul 17, 2026Total Debt (MRQ)
23.17MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1599xvs Biotechnology peers
Current Ratio (MRQ)
5.89xvs Biotechnology peers
Book Value per Share (MRQ)
2.55USDUpdated Jul 17, 2026Total Assets
219.57MUSDvs all stocks (USD)
Total Current Assets
204.91MUSDFY2025 · Dec 31, 2025Total Liabilities
60.35MUSDFY2025 · Dec 31, 2025Total Non-current Assets
14.66MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
30.78MUSDFY2025 · Dec 31, 2025Total Current Liabilities
29.57MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
78.44MUSDFY2025 · Dec 31, 2025Other Short-term Investments
112.97MUSDFY2025 · Dec 31, 2025Accounts Receivable
6.15MUSDFY2025 · Dec 31, 2025Inventory
5.49MUSDFY2025 · Dec 31, 2025Accounts Payable
7.89MUSDFY2025 · Dec 31, 2025Short-term Debt
13.09MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.00KUSDFY2025 · Dec 31, 2025Long-term Debt
11.88MUSDFY2025 · Dec 31, 2025Common Stock (Book)
550.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-742.08MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
159.22MUSDvs all stocks (USD)
52-Week Low
4.00USDUpdated Jul 17, 202652-Week High
7.54USDUpdated Jul 17, 202652-Week Change
7.81%vs all stocks
Beta
1.33xvs all stocks
50-Day MA
5.83USDUpdated Jul 17, 2026200-Day MA
5.25USDUpdated Jul 17, 2026Avg 10-Day Volume
1.55MSharesUpdated Jul 17, 2026Avg 30-Day Volume
1.34MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
0.9500USDUpdated Jul 17, 2026Other Income / Expense
158.91MUSDFY2025 · Dec 31, 20256 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Diagnostic
High ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
Return on equity reads high, with a large gap between pretax and operating income.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 454.9%, higher than 95% of its Biotechnology peers (median -45.7%)Significant
Profit margin: 4.55Industry median: -0.46Industry P95: 0.43Peers compared: 261
Return on equity is 71%, higher than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: 0.71Industry median: -0.22Industry P95: 0.23Peers compared: 261
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 66,137,000Operating Cash Flow (USD, TTM): -77,728,000
Financial Health
Altman Z-Score 1.36: grey zoneSignificant
Altman Z-Score: 1.36
Low earnings qualitySignificant
Earnings Quality Score: -0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $14.54M, lower than 95% of all stocks globallySignificant
Revenue (USD): 14,540,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Bioeasy Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aarti Drugs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Blau Farmacêutica S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Century Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
Crescent Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Kamada Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Foresee Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Sun Corporation
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedCash-Flow Ratios ElevatedHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
ASTERA LABS INC COMMON STOCK (Ticker: 1ALAB)
5 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedCash-Flow Ratios Elevated
Shanghai New Power Automotive Technology Co., Ltd.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedCash-Flow Ratios ElevatedHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration